With global inflation still under watch and US 10 year yields pushing toward multi month highs, income investors are again asking what really justifies a risk premium. Reliable dividend payers that keep distributing cash even as borrowing costs stay elevated can look especially appealing. This Dividend Powerhouses screener focuses on yields above 5% that appear well covered, growing and stable. This article highlights three standouts that may warrant closer attention.
The three stocks that follow are just a starting sample, and the full Dividend Powerhouses screen surfaced 26 more companies with equally compelling income stories that are not covered below. If you want to quickly sort through the wider opportunity set, head straight into the Dividend Powerhouses (3%+ Yield) screener to identify, compare and analyze the highest conviction dividend ideas.
CSL (ASX:CSL)
CSL is a global biopharmaceutical group that develops and manufactures plasma therapies, vaccines and specialty medicines for serious conditions where patients often have few alternatives. Most revenue comes from CSL Behring at about US$10.9b, with CSL Seqirus flu vaccines adding roughly US$2.2b and CSL Vifor iron and kidney treatments about US$2.4b. The company is large in scale at around A$65.4b in market value.
Income focused investors may find CSL interesting because it couples a 3% yield with a portfolio of essential therapies, including a large plasma franchise and an expanding rare disease pipeline. The recent earnings hit and heavy restructuring, plus high debt and thinner margins, mean this is not a low risk story. Yet fresh Phase 3 data for ANDEMBRY and forecasts for stronger earnings recovery hint that the current share price may not fully reflect the long term potential.
CSL’s earnings reset and restructuring could be masking the significance of its essential therapies and plasma portfolio for potential future income strength. Get the full picture in the 2 key rewards and 4 important warning signs
Build your own dividend powerhouse shortlist
CSL and the two other stocks in this list all came from a single Simply Wall St screen, but the real edge comes when you tailor the filters yourself. Use our configurable Screener to mix factors like yield, payout strength, balance sheet and risks, or tap into curated themes with our Investing Ideas.
Computershare (ASX:CPU)
Computershare runs share registries, corporate trust, employee share plans and communication services that sit at the plumbing of global capital markets. Most revenue comes from Issuer Services at about $1.3b and Corporate Trust at about $1.0b, with Employee Share Plans adding roughly $586 million and smaller contributions from Corporate and Other, after accounting for intersegment items. The company is sizeable at around A$23.4b in market value.
Income investors may want to look at Computershare because it couples exposure to core registry and corporate trust activities with a business that is investing in digitization and AI to lift efficiency and margins. Management revenue and earnings per share have both improved in the latest full year, the balance sheet supports ongoing buybacks, yet the stock is still sensitive to interest rate cuts that could hit Margin Income and it relies heavily on a few core engines as it exits US mortgage servicing. The recent A$0.65 dividend and client registry moves highlight both the appeal and the competitive pressure. This makes the underlying income profile worth a closer look beyond the headline yield.
Computershare’s push into digitization and AI could be masking how its core engines really support your income thesis. See how the balance sheet, payout and rate sensitivities all fit together in the Computershare financial health report
Commonwealth Bank of Australia (ASX:CBA)
Commonwealth Bank of Australia is one of the largest banks in the country, offering everyday accounts, savings, home loans, business lending, payments and insurance across Australia, New Zealand and other markets. It generates most of its revenue from Retail Banking Services at about A$13.4b and Business Banking at around A$9.7b, with smaller contributions from New Zealand at A$2.9b and Institutional Banking and Markets at A$2.9b. The company is large in scale with a market value of roughly A$279.5b.
Income investors looking at Commonwealth Bank of Australia get a mix of high quality earnings, a fully franked dividend and ongoing buybacks, backed by strong capital and deposit funding. At the same time, the stock trades on a rich P/E and analysts see the current price above their consensus target. This makes the payout, cost discipline and AI driven efficiency program critical to watch. With earnings growth, solid net profit margins around the mid 30s and a push to use AI to trim costs and support digital services, the key question is whether today’s valuation still leaves enough room for long term dividend and capital return potential.
Commonwealth Bank of Australia’s rich P/E and strong capital position suggest the story is more complex than a simple dividend play. See how the valuation, payout strength and AI efficiency push connect in the analysis report for Commonwealth Bank of Australia
Seeking Alternatives Before The Crowd Moves
Fresh income ideas can move from quiet to crowded fast. Spot potential breakouts and stocks building momentum while they are still under the radar for now. Act now.
- Catch quality companies before they are widely talked about by scanning the 11 high quality undiscovered gems, a tool that screens for strong fundamentals hiding in plain sight.
- Hunt for resilient payers and cash generators using the list of solid balance sheet and fundamentals (20 results), which filters for robust finances while weaker stocks are still dropping away.
- Target steady compounders with lower risk profiles through the 10 resilient stocks with low risk scores, a screener that highlights businesses built to handle more than one market cycle.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com